Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Acute Effects of Focal Vibration on Posterior Shoulder Tightness and Tissue Stiffness in Overhead Athletes

NCT07757945 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-02-05
Last updated
2026-08-11

Condition(s) studied

Posterior Shoulder Tightness

Investigational drug(s) / intervention(s)

Focal VibrationSham Focal Vibration

Focal Vibration: A standardized single-session focal vibration intervention applied to the posterior shoulder muscles using fixed vibration parameters. The protocol is designed to evaluate the immediate effects of focal vibration on posterior shoulder tightness and related shoulder functions in overhead athletes and includes a sham-controlled comparison to distinguish treatment effects from placebo.

Sham Focal Vibration: The sham focal vibration intervention is performed using the same device, application duration, and application site as the active intervention. However, the device is configured not to deliver therapeutic vibration. This approach is intended to maintain participant blinding and to determine whether the observed effects are attributable to focal vibration rather than placebo effects.

Study summary

This study aims to investigate the acute effects of focal vibration on posterior shoulder tightness, posterior shoulder muscle stiffness, and glenohumeral range of motion in overhead athletes. A total of 36 overhead athletes aged 18-25 years who have regularly participated in overhead sports for at least four years will be included. Participants will be randomly allocated to either the focal vibration group or the sham control group using block randomization. All outcome assessments will be performed immediately before and immediately after a single intervention session.

The primary outcome measure is posterior shoulder tightness, assessed using the Horizontal Adduction Test. Secondary outcome measures include posterior shoulder muscle stiffness, assessed using the IndentoPRO digital tissue indentometer, and passive glenohumeral internal and external rotation range of motion, measured using the GYKO inertial sensor.

The primary research question is whether focal vibration has an acute effect on posterior shoulder tightness, muscle stiffness, and glenohumeral range of motion in overhead athletes. It is hypothesized that participants receiving focal vibration will demonstrate greater reductions in posterior shoulder tightness and muscle stiffness, as well as greater improvements in glenohumeral range of motion, compared with those receiving the sham intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: Aged between 18 and 25 years. Regular participation in an overhead sport for at least 4 years. Participating in regular training at least 4 times per week. Willing to participate voluntarily in the study and able to provide written informed consent. Exclusion Criteria: History of shoulder surgery within the previous 6 months. History of shoulder, neck, or upper extremity injury within the previous 3 months. Participation in intense upper extremity training within the previous 48 hours. Presence of infection, skin lesions, or open wounds around the shoulder region. Diagnosis of a systemic rheumatologic or neurological disease. Unwillingness to participate in the study or refusal to provide written informed consent.

Primary outcome measure(s)

  • Posterior Shoulder Tightness (Horizontal Adduction Test) — Immediately before and immediately after a single intervention session
    Posterior shoulder tightness will be assessed using the Horizontal Adduction Test. Participants will lie in the supine position while the scapula is stabilized by the examiner. The shoulder will be passively moved into horizontal adduction until the first point of scapular movement is detected. The horizontal adduction angle will be measured using a digital inclinometer. Lower values indicate greater posterior shoulder tightness, whereas higher values indicate improved shoulder flexibility.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Physiotherapy and Rehabilitation, University of Health Sciences Ankara Ankara Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07757945 on ClinicalTrials.gov ↗ ← All trials in Turkey